Electronic cigarettes or "e-cigarettes" (EC) may have a potential public health benefit as a safer alternative to smoking and possibly also as an aid in tobacco dependence treatment. However, there are concerns about their safety and whether they can deliver nicotine consistently and in doses necessary for such effects. To be able to consider the safety of ECs and their potential in harm reduction, data are needed comparing the exposure to the potential toxicant, acrolein, in smokers of conventional cigarettes, users of EC, and people who use both products at the same time. To accurately assess EC nicotine delivery, data are needed from people who use them regularly, as there is some evidence of higher and faster nicotine absorption in experienced users compared with naïve users who try them once in an artificial laboratory setting. This study will provide information on both of these issues. Forty smokers will be given EC to use, in addition to behavioural support, as part of a stop smoking attempt. Levels of acrolein and nicotine will be measured before and after 4 weeks of EC use.
Study Type
OBSERVATIONAL
Enrollment
40
Queen Mary University of London
London, United Kingdom
Change in urinary 3HPMA levels after 4 weeks use of electronic cigarettes.
Change in urinary 3HPMA levels (a metabolite of acrolein) after 4 weeks use of electronic cigarettes, in both individuals who have stopped smoking conventional cigarettes and those who are still using them.
Time frame: 4 weeks
Change in nicotine levels after 4 weeks use of electronic cigarettes (EC)
Change in blood nicotine levels obtained from using an EC after 4 weeks use of electronic cigarettes (10 participants only).
Time frame: 4 weeks
Electronic cigarette acceptability
Participants' views on electronic cigarettes
Time frame: 6 months
Use of electronic cigarettes
Participants' use of electronic cigarettes
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.